Natera (NTRA) issued the following statement regarding its ongoing patent infringement litigation with NeoGenomics (NEO) in response to inquiries: “On Sept. 23, 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023. Natera continues to prosecute its claim against a modified version of RaDaR for infringement of Natera’s ‘454 patent. Natera seeks full remedies, including injunctive relief, after the Patent Office denied NeoGenomics’ petition for ‘inter partes’ review challenging the validity of the ‘454 patent.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $150 from $135 at BTIG
- Natera announces new data from GALAXY arm of ongoing CIRCULATE-Japan trial
- Natera ALTAIR data readout could drive guideline inclusion, says Canaccord
- Election 2024: Where To Put Your Money Ahead of the Vote
- Natera price target raised to $145 from $130 at Canaccord